Drug intelligence / Profile preview

tunlametinib + pucotenlimab + hydroxychloroquine

Development stage: Unknown
Lead developer: Shanghai KeChow Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Tunlametinib + pucotenlimab + hydroxychloroquine is an investigational triple-drug combination therapy being evaluated for the treatment of locally advanced or metastatic NRAS-mutant melanoma. The regimen combines tunlametinib (HL-085), a potent and selective oral small-molecule MEK1/2 inhibitor; pucotenlimab (HX008), an anti-PD-1 monoclonal antibody; and hydroxychloroquine, a small-molecule autophagy inhibitor. The combination aims to overcome resistance and enhance anti-tumor activity by modulating the MAPK/RAS-RAF signaling pathway, blocking the PD-1/PD-L1 immune checkpoint, and inhibiting autophagy-mediated lysosomal degradation to increase tumor immunogenicity. A Phase 2 clinical trial sponsored by Sun Yat-sen University is currently investigating the efficacy and safety of this triplet in patients with NRAS-mutated advanced melanoma.

Brand names: 科露平Puyouheng
Other names: tunlametinib + pucotenlimab + hydroxychloroquine

Targets

PDCD1 (Programmed cell death protein 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on tunlametinib + pucotenlimab + hydroxychloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tunlametinib + pucotenlimab + hydroxychloroquine.

Explore the full profile